Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 20/20 | 0.67 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.67 |
| ▸ | CDK2 | P24941 | 1/20 | 0.67 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062636 | 0.83 | PLK1 (0.69) | PLK1PLK3 | |
| SCHEMBL5065731 | 0.81 | PLK1 (0.82) | PLK1PLK3CDK2IKBKE | |
| SCHEMBL4032126 | 0.81 | PLK1 (0.78) | PLK1PLK3CDK2IKBKE | |
| Gsk-237701A SCHEMBL29644977 | 0.81 | PLK1 (1.00) | PLK1PLK3CDK2IKBKE | |
| Gsk-237701A SCHEMBL5065885 | 0.81 | PLK1 (1.00) | PLK1PLK3CDK2IKBKE | |
| Gsk-237701A SCHEMBL4034890 | 0.81 | PLK1 (1.00) | PLK1PLK3CDK2IKBKE | |
| SCHEMBL4032849 | 0.80 | IKBKE (0.68) | PLK1PLK3IKBKE | |
| SCHEMBL5058239 | 0.79 | PLK1 (1.00) | PLK1PLK3 | |
| SCHEMBL14344449 | 0.79 | PLK1 (0.81) | PLK1PLK3CDK2IKBKE | |
| SCHEMBL5062450 | 0.79 | PLK1 (0.66) | PLK1PLK3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720864-B1 | BENZIMIDAZOL SUBSTITUTED THIOPHENE DERIVATIVES WITH ACTIVITY ON IKK3 | GLAXO GROUP LTD (GB) | 2009-05-06 | — | — | EP | disclosed |
| US-20070149519-A1 | Benzimidazol substituted thiopene derivatives with activity on ikk3 | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149519-A1 | Benzimidazol substituted thiopene derivatives with activity on ikk3 | IKBKE, IKBKB, TBK1 | PLK1 1088/4885PLK3 413/4885CDK2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.